Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
JICC01 - Joint IASLC-CAALC-CSCO Session: The Truth and Myth of Oral Anti-VEGFR Inhibitors for Advance NSCLC
- 07:00 - 09:00
- 1/28/2021
- Location: Scientific Program Auditorium
- Not for CME Credit
- Type: Workshop
- Track: N.A.
-
+
JICC01.12 - Molecular Landscape of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Chinese Advanced Non-Small Cell Lung Cancer
08:30 - 08:35 | Presenter: Xiaomin Niu
- Abstract
Loading...
-
+
FP12 - Tumor Biology and Systems Biology - Basic and Translational Science
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
-
+
FP12.05 - Molecular Landscape of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Chinese Advanced Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Xiaomin Niu
- Abstract
Loading... -
+
FP12.13 - Therapeutic Index Predicts Clinical Outcome of both Treated and Treatment-Naïve NSCLC Patients Receiving Targeted- and Immune-Therapy
00:00 - 00:00 | Presenter: Xiaomin Niu
- Abstract
Loading...
-
+
P33 - Pathology - Immunotherapy Biomarker
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
-
+
P33.07 - Peripheral CD4+ T cell Signatures in Predicting Response to Anti-PD-1 Monotherapy for Chinese Advanced Non-Small Cell Lung Cancer Patients
00:00 - 00:00 | Presenter: Ying Wang
- Abstract
Loading...
-
+
P35 - Pathology - Genomics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
-
+
P35.23 - Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma with Micropapillary Component
00:00 - 00:00 | Presenter: Yang Xu
- Abstract
Loading...
-
+
P42 - Screening and Early Detection - Risk Modelling and Artificial Intelligence
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Screening and Early Detection
-
+
P42.03 - A Dynamic Deep Learning Approach to Predict Clinical Outcomes of Patients with Advanced Non-Small Cell Lung Cancer under Nivolumab Monotherapy
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading...
-
+
P72 - Tumor Biology and Systems Biology - Basic and Translational Science - Tumor Microenvironment
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
-
+
P72.06 - NLRP4-Mediated Type I Interferon Response Benefits Immune Checkpoint Therapy Through Redirecting CD8+ T Cell Distribution in TME
00:00 - 00:00 | Presenter: Liliang Xia
- Abstract
Loading...
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P76.66 - Real-World, First-Line Osimertinib Treatment in Epidermal Growth Factor Receptor Mutation-Positive (EGFRm) Advanced NSCLC
00:00 - 00:00 | Presenter: Jorge Nieva
- Abstract
Loading... -
+
P76.93 - The Efficacy of Second-Line Osimertinib Plus Bevacizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading...
-
+
P79 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P79.03 - A Phase 3 Study of the PD-1 Inhibitor Retifanlimab (INCMGA00012) Plus Platinum-Based Chemotherapy in 1L mNSCLC: POD1UM-304
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading... -
+
P79.08 - Sintilimab ± IBI305 Plus Chemotherapy for Patients With EGFR-Mutant Non-Squamous NSCLC Failed to EGFR-TKI Treatment
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading...
-
+
OA06 - Updates on EGFR Targeted Perioperative Therapy and Precision Adjuvant Chemotherapy
- 16:45 - 17:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Early Stage/Localized Disease
-
+
OA06.03 - Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC
16:45 - 16:55 | Presenter: Margarita Majem
- Abstract
Loading... -
+
OA06.04 - Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC
16:55 - 17:05 | Presenter: Yi-long Wu
- Abstract
Loading...
